NASDAQ:VCYT Veracyte (VCYT) Stock Forecast, Price & News $22.47 -0.13 (-0.58%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$22.21▼$22.9850-Day Range$22.47▼$29.9252-Week Range$14.92▼$32.40Volume439,060 shsAverage Volume482,328 shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice Target$30.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Veracyte MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside36.2% Upside$30.60 Price TargetShort InterestHealthy3.49% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.79Based on 2 Articles This WeekInsider TradingSelling Shares$305,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.52) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector347th out of 963 stocksMedical Laboratories Industry8th out of 23 stocks 3.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.60, Veracyte has a forecasted upside of 36.2% from its current price of $22.47.Amount of Analyst CoverageVeracyte has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.49% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Veracyte has recently decreased by 11.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 67.08% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Genomics analysis tools", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.03. Previous Next 2.1 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Veracyte this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $305,000.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Veracyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.52) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -56.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -56.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Veracyte (NASDAQ:VCYT) StockVeracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comVeracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual MeetingSeptember 15, 2023 | es.investing.comVeracyte Inc (VCYT)September 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 7, 2023 | finance.yahoo.comVeracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s TestsSeptember 6, 2023 | finance.yahoo.comVeracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer TherapiesSeptember 2, 2023 | msn.comIs This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?August 29, 2023 | businesswire.comVeracyte to Participate in the Morgan Stanley 21 st Annual Global Healthcare ConferenceAugust 29, 2023 | finance.yahoo.comVeracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 24, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 17, 2023 | seekingalpha.comVeracyte: Testing Numbers Stretching Higher But Valuations UncertainAugust 15, 2023 | finance.yahoo.comVeracyte Earns Top Workplace Awards in the San Francisco Bay Area and San DiegoAugust 10, 2023 | msn.comMorgan Stanley Maintains Veracyte (VCYT) Underweight RecommendationAugust 9, 2023 | msn.comNeedham Maintains Veracyte (VCYT) Buy RecommendationAugust 8, 2023 | seekingalpha.comVeracyte, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 8, 2023 | finance.yahoo.comVeracyte Announces Second Quarter 2023 Financial ResultsJuly 25, 2023 | benzinga.comDirector At This Health Care Company Sells $118K of StockJuly 19, 2023 | finance.yahoo.comVeracyte to Release Second Quarter 2023 Financial Results on August 8, 2023June 20, 2023 | finance.yahoo.comNew Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and CancerJune 12, 2023 | benzinga.comVeracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023May 30, 2023 | finance.yahoo.comVeracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some InvestorsMay 25, 2023 | benzinga.comNew Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate CancerMay 24, 2023 | finance.yahoo.comNew Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung CancerMay 22, 2023 | finance.yahoo.comHere's Why This Little-Known Growth Stock Is a BuyMay 17, 2023 | msn.comLooking Into Veracyte's Return On Capital EmployedMay 16, 2023 | seekingalpha.comVeracyte: Investing In The Future Of Genomic DiagnosticsMay 10, 2023 | theglobeandmail.comA New Groundbreaking Tool to Detect Colon Cancer EarlierMay 10, 2023 | msn.comStephens & Co. Reiterates Veracyte (VCYT) Overweight RecommendationSee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Company Calendar Last Earnings8/08/2023Today9/24/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees787Year Founded2006Price Target and Rating Average Stock Price Forecast$30.60 High Stock Price Forecast$35.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+36.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,560,000.00 Net Margins-8.84% Pretax Margin-8.73% Return on Equity-2.71% Return on Assets-2.53% Debt Debt-to-Equity RatioN/A Current Ratio4.46 Quick Ratio4.26 Sales & Book Value Annual Sales$296.54 million Price / Sales5.51 Cash FlowN/A Price / Cash FlowN/A Book Value$14.98 per share Price / Book1.50Miscellaneous Outstanding Shares72,750,000Free Float70,859,000Market Cap$1.63 billion OptionableOptionable Beta1.32 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 53)CEO & Director Comp: $1.25MMs. Rebecca Chambers (Age 45)Exec. VP & CFO Comp: $772.41kMs. Annie McGuire (Age 42)Exec. VP, Gen. Counsel & Chief People Officer Comp: $633.65kMr. Jonathan Wygant (Age 52)VP & Chief Accounting Officer Mr. Steven FrenchSr. VP & Chief Information OfficerMs. Tracy MorrisVP of Global Corp. CommunicationsMr. Robert Brainin (Age 51)Exec. VP & Chief Bus. Officer Dr. Fabienne Hermitte Ph.D.Sr. VP of Global Quality & Regulatory AffairsDr. John Leite Ph.D.Chief Commercial Officer for CLIA Bus.Ms. Corinne DananSr. VP and GM of Biopharma & IVD ServicesMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXLigand PharmaceuticalsNASDAQ:LGNDCaribou BiosciencesNASDAQ:CRBUArcellxNASDAQ:ACLXDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 31,517 shares on 9/21/2023Ownership: 0.244%Portside Wealth Group LLCBought 44,877 shares on 9/1/2023Ownership: 0.062%Comerica BankBought 10,836 shares on 8/22/2023Ownership: 0.015%California State Teachers Retirement SystemSold 1,991 shares on 8/21/2023Ownership: 0.121%Teachers Retirement System of The State of KentuckyBought 4,713 shares on 8/21/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions VCYT Stock - Frequently Asked Questions Should I buy or sell Veracyte stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks. What is Veracyte's stock price forecast for 2023? 6 brokers have issued 1-year price targets for Veracyte's stock. Their VCYT share price forecasts range from $23.00 to $35.00. On average, they predict the company's stock price to reach $30.60 in the next year. This suggests a possible upside of 36.2% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts. How have VCYT shares performed in 2023? Veracyte's stock was trading at $23.73 on January 1st, 2023. Since then, VCYT stock has decreased by 5.3% and is now trading at $22.47. View the best growth stocks for 2023 here. When is Veracyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our VCYT earnings forecast. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) announced its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. The biotechnology company earned $90.32 million during the quarter, compared to analysts' expectations of $83.05 million. Veracyte had a negative trailing twelve-month return on equity of 2.71% and a negative net margin of 8.84%. Veracyte's revenue for the quarter was up 24.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.13) earnings per share. What ETFs hold Veracyte's stock? ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW). What guidance has Veracyte issued on next quarter's earnings? Veracyte issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$350.00 million, compared to the consensus revenue estimate of $335.77 million. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). What is Veracyte's stock symbol? Veracyte trades on the NASDAQ under the ticker symbol "VCYT." Who are Veracyte's major shareholders? Veracyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (48.69%), ARK Investment Management LLC (10.81%), BlackRock Inc. (9.50%), State Street Corp (4.97%), Artisan Partners Limited Partnership (4.89%) and Sumitomo Mitsui Trust Holdings Inc. (4.49%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, John Walter Hanna Jr, Karin Eastham, Kevin K Gordon, Marc Stapley, Mark Ho and Muna Bhanji. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Veracyte's stock price today? One share of VCYT stock can currently be purchased for approximately $22.47. How much money does Veracyte make? Veracyte (NASDAQ:VCYT) has a market capitalization of $1.63 billion and generates $328.63 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How many employees does Veracyte have? The company employs 787 workers across the globe. Does Veracyte have any subsidiaries? The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.Read More How can I contact Veracyte? Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301. This page (NASDAQ:VCYT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.